DRCR.net Protocol W
Anti-VEGF Treatment for Prevention of Proliferative Diabetic Retinopathy and Diabetic Macular Edema
Multiple studies have implicated vascular endothelial growth factor (VEGF) as a major causative factor in human eye diseases characterized by neovascularization, including proliferative diabetic retinopathy (PDR) and vascular permeability, including diabetic macular edema (DME). While there is strong evidence that PDR outcomes are markedly reduced in eyes that are treated with monthly anti-VEGF therapy (A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus: RIDE/RISE) and moderately reduced in eyes that received fairly frequent dosing during the 1st year of treatment (Diabetic Retinopathy Clinical Research Network protocol I), it is unknown whether or not an earlier but less frequent dosing regimen would result in similar, favorable anatomic outcomes, and whether favorable anatomic outcomes subsequently would result in favorable visual acuity outcomes.
For more information regarding this trial see: